presidentDonald TrumpOn Monday, a sweeping executive set a final date for 30 days for drug makers to reduce the cost of medicines prescribed in the United States or face new borders on the road on what the government will pay.
The request is called to the health department, ledRobert F. Kennedy JuniorThe mediation has new price signs for drugs during the next month. If there are no deals, Kennedy will be assigned to develop a new base linking the price of the United States to the drug to the low prices paid by other countries.
“We will draw,” Trump said at a press conference on Monday morning. “We will pay the same thing. We will pay what Europe pays.”
It is not clear what will affect – if any – the executive order of the Republican President on millions of Americans who have special health insurance. The federal government has the greatest strength to form the price it pays to Medicare and Medicaid.
The new Trump savings-but not confirmed-at drug prices, just hours after the Republican Parliament was issuedHer new plan to reduce $ 880 billion from Medicaid.
Taxers spendHundreds of billions of dollarsOn prescribed medications, injections, transportation and other medicines every year through medical care, which cover nearly 70 million Americans. Medicaid, which provides almost free health care for about 80 million poor and handicapped people in the United States as wellTens of billions of dollars spendEvery year of drugs.
The U.S. drug makers say Trump is bad for patients
The lobby responded in the nation, which represents the best drug makers in the United States, immediately against Trump’s order, describing it as a “bad deal” for American patients. Pharmaceutical makers have long argued that any threats to their profits can affect their research to develop new drugs.
Stephen J. Opel, President and CEO of PHRMA, in a statement “Import foreign prices from socialist countries will be a bad deal for American patients and workers.” “This means that treatments and treatments are less and will endanger the hundreds of billions that our member companies are planning to invest in America.”
The so -called “the most preferred nation” in pricing medical medicines has been controversial since he first tried to implement it during its first term. He fellSimilar executiveIn the last weeks of his presidency, which called for the United States only a fewer price paid by other countries – such as injections or cancer drugs provided through the payments – that are given in the doctor’s office.
This narrow executive order faced obstacles, withCourtThis prevented the base from going into force during the era of President Joe Biden. The pharmaceutical industry has argued that Trump’s 2020 attempt will give foreign governments the “upper hand” in determining the value of medicines in the United States
Trump says that other countries should blame
Trump has repeatedly defended the pharmaceutical companies, instead blames other countries against the high price that the Americans pay against drugs, during a large -scale speech at the White House on Monday. The president was surrounded by Kennedy, the centers of the Director of Medical Care and Medical Services, Dr. Mahham Oz, the Food and Drug Administration Commissioner, Dr. Marti Makari, and the National Director of Health Director, Jay Bahtasharia.
However, companies may threaten federal investigations in their practices and open the American drug market to bring more drugs imported from other countries.
“Pharmaceutical companies are achieving most of its profits from America,” Trump said. “This is not a good thing.”
Trump played this advertisement during the weekend, boasting in one post that his plan can provide “trillion dollars”.
But on Monday, the White House did not provide any details about the amount of money that the administration expects to provide.
Senior leaders of the Ministry of Health will meet with the executives of the drug company over the next thirty days to provide new prices on drugs that are based on what other countries pay, Oz said on Monday.
The Americans are unlikely to see immediate savings
Rachel Sachs, a Washington University’s health expert, said they are unlikely to see the high costs of drug costs because of the matter.
“It seems really that the plan is to ask manufacturers voluntarily to reduce their prices to a point, which is unknown,” said Sachs. “If they do not lower their prices to the required point, HHS must take other measures with a very long time schedule, some of which may be likely, for years in the future, less than drug prices.”
The Ministry of Health has the largest amount of changing prices of medicines covered by Medicare and Medicaid because it can determine the regulations. Even so, the agency’s authority to do so is limited. Congress has just agreed in 2022New lawThis allows medical care to negotiate the price he pays for a handful of prescribed drugs that begin in 2026. Before the law, Medicare paid what pharmaceutical companies followed. Pharmaceutical companies filed a lawsuit against the implementation of the law without success.
The price covered by millions of Americans with special insurancePayIt is difficult for the agency to manipulate.
The United States routinely outperforms other countries over the prices of medicines, compared to large and wealthy countries, a problem that has long been exposed to the anger of both the two main political parties, but permanent reform has never been deposed.
Trump entered his first term that accused the pharmaceutical companies of “avoiding killing” and complaining that other countries whose governments determine the prices of medicines benefit from Americans.
Trump says he will “do the right thing”
Before the announcement, Trump dismantled his speech towards industry again on social media, where he wrote that “pharmaceutical companies/medicines will say, for years, that the costs of research and development, and that all these costs were, and will be, without any reason, without any reason, by” photographers “in America, alone.”
In reference to the strong pressure efforts of the pharmaceutical companies, he said that the campaign’s contributions “can do wonders, but not with me, not with the Republican Party.”
“We will do the right thing,” he wrote.
Many pharmaceutical companies have gained ground in the stock market on Monday morning. MerkThe company, which achieved $ 64.2 billion last year with the help of Keytruda Cancer Treatment, jumped by 3.9 %. Medicine giant VizarWhich achieved revenue of $ 63.6 billion in 2024, increased by 2.5 % Glyid science 5.8 % increased.
This story was originally shown on Fortune.com
https://fortune.com/img-assets/wp-content/uploads/2025/05/GettyImages-2214701911.jpg?resize=1200,600
Source link